08:00 - Registration and breakfast
09:00 - Introductory remarks
Marco de Morpurgo - Global Co-Chair, Life Sciences Sector, DLA Piper
09:15 - Life Sciences: 2034 and Beyond
Dr. Lyndsey Hudson - Head of Strategic Delivery, Life Sciences, DLA Piper
09:45 - What is driving the market?
Bill Burkoth, Managing Partner, Life Sciences, Forest Road
Dr Karl Keegan, Head, Equity Research, Singer Capital Markets
Jeff Baglio, Partner, DLA Piper
10:15 - Spotlight on ESG & Sustainability
Tom Heylen, Co-Lead, International Life Sciences Corporate, DLA Piper
Shaun Walden, Head of ESG UK & Europe, DLA Piper
10:30 - Coffee break
11:00 - Political challenges facing the industry
Former US Senator Richard Burr, Principal Policy Advisor, DLA Piper
Former European Commissioner Phil Hogan, Senior Strategic and Political Advisor, DLA Piper
11:30 - EU pharmaceutical law reform: Where are we (heading to)?
Former Head of EMA Legal Department Stefano Marino, Senior Consultant, DLA Piper
12:00 - Morning wrap-up
Lisa LeCointe-Cephas - Global Co-Chair, Life Sciences Sector, DLA Piper
12:15 - Lunch and networking
13:30 - Breakout session 1:
(Select one session to attend)
M&A trends in the current environment
Dr. Gil Bar-Nahum, Jefferies International Limited
Michael Stewart, Sanofi
Howard Taylor, Rosemont Pharmaceuticals
Andy Gilbert, DLA Piper
Victoria Rhodes, DLA Piper
Protecting innovation: regulatory incentives in the EU, US, and China
Victoria Kitcatt, Pfizer
Geoff Levitt, argenx
Marco de Morpurgo, DLA Piper
Stefano Marino, DLA Piper
Ting Xiao, DLA Piper
Antitrust’s ever increasing impact on Life Sciences – an in-house perspective
Karolina Czernicka-Kuhl, Vertex
Julie Marot, Medtronic
Joost Haans, DLA Piper
Amadeu Ribeiro, DLA Piper
14:10 - Break
14:25 - Breakout session 2:
(Select one session to attend)
Going viral: the global expansion of class actions and mass torts against Life Sciences companies
Dr. Kirsten Sowade, Bayer AG
Chris Campbell, DLA Piper
Siona Spillett, DLA Piper
Jeremy Sher, DLA Piper
Best practices for managing global patent disputes
Gualtiero Dragotti, DLA Piper
Rebecca Lawrence, DLA Piper
Aoife Murphy, DLA Piper
Kokularajah Paheenthararajah, DLA Piper
Ellen Scordino, DLA Piper
Nick Tyacke, DLA Piper
Data for good: implementing effective data governance to unlock value
Georgie Dowdell, Otsuka Pharmaceutical
Greg Bodulovic, DLA Piper
James Clark, DLA Piper
Kristi Kung, DLA Piper
15:05 - Break
15:20 - Breakout session 3:
(Select one session to attend)
Managing investigations risk: what do I need to know?
Christina Jordan, Bristol Myers Squibb
Lisa LeCointe-Cephas, DLA Piper
Adam Vause, DLA Piper
Aurelie Ercoli, DLA Piper
Trans-Atlantic alignment and convergence in Healthcare policy
Karina Lynch, DLA Piper
Jamie Gregorian, DLA Piper
Richard Sterneberg, DLA Piper
Nightmares in Life Sciences contracting and how to avoid them
Michaela Zabbo, GE Healthcare
Irina Macovei, DLA Piper
Lauren Murzda, DLA Piper
Richard Taylor, DLA Piper
16:00 - Break
16:15 - AI: unlocking the future of the Life Sciences industry
Debbi Bolton, Life Sciences Consultant, Strix Associates
Benjamin Meany, Manager Digital, Software and AI Regulation, MedTech Europe
Imogen Palmer, AI GTM Strategy & Customer Activation, Google
Danny Tobey, Co-Chair, Global AI Group, DLA Piper
Gareth Stokes, Co-Chair, Global AI Group, DLA Piper
16:55 - Closing remarks
Marco de Morpurgo - Global Co-Chair, Life Sciences Sector, DLA Piper
17:00 - Cocktail reception
